News
)
15 January 2025
VIVEbiotech named finalist for CMO/CDMO of the Year at Advanced Therapies Awards
Excitement builds as our team heads to Dallas for Advanced Therapies Week conference.
Read more)
8 January 2025
VIVEbiotech’s Expertise Highlighted in Drug Discovery World’s 2025 Predictions
Natalia Elizalde shares insights on the future of cell and gene therapy.
Read more)
20 December 2024
Merry Christmas and Happy New Year from our extraordinary team
As the year winds down, we’re filled with gratitude for the incredible journey that was 2024 for VIVEbiotech.
Read more)
16 December 2024
VIVEbiotech will be exhibiting at the Advanced Therapies Week in Dallas
VIVEbiotech will be an exhibitor at Phacilitate's Advanced Therapies Week to be held in Dallas from January 20-23.
Read more)
4 December 2024
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private equity...
Read more)
25 October 2024
VIVEbiotech publishes new research paper
We’re thrilled to announce that our latest research paper entitled “Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing...
Read more)
24 October 2024
Active participation of VIVEbiotech at the ESGCT´s 31st annual meeting
The European Society of Gene and Cell Therapy´s annual congress is in full swing.
Read more)
10 October 2024
VIVEbiotech participates one more year in the Innovative Therapies Days
VIVEbiotech is participating as a Silver Sponsor in Innovative Therapies Days, a 2-day conference that takes place every year in Besançon, in the R...
Read more)
8 October 2024
VIVEbiotech participates in Cell & Gene Meeting on the Mesa
As in several past editions, VIVEbiotech is participating in Cell & Gene Meeting on the Mesa.
Read more)
18 September 2024
Q&A in GEN with Natalia Elizalde
Natalia Elizalde, our Chief Business Development Officer at VIVEbiotech, recently shared her expertise with GEN on the increasing demand for lentiviral vectors, of which we...
Read more)
)
)
)
)
)
)
)
)
)